Global Blinatumomab Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 119907
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Blinatumomab market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Blinatumomab market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Blinatumomab global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Prefilled segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of Blinatumomab include Amgen, , , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Blinatumomab market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Prefilled

Non-prefilled

Market segment by Application can be divided into

Hospital

Pharmacy

The key market players for global Blinatumomab market are listed below:

Amgen

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Blinatumomab product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Blinatumomab, with price, sales, revenue and global market share of Blinatumomab from 2019 to 2022.

Chapter 3, the Blinatumomab competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Blinatumomab breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Blinatumomab market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Blinatumomab.

Chapter 13, 14, and 15, to describe Blinatumomab sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Blinatumomab Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global Blinatumomab Revenue by Type: 2017 Versus 2021 Versus 2028

1.2.2 Prefilled

1.2.3 Non-prefilled

1.3 Market Analysis by Application

1.3.1 Overview: Global Blinatumomab Revenue by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospital

1.3.3 Pharmacy

1.4 Global Blinatumomab Market Size & Forecast

1.4.1 Global Blinatumomab Sales in Value (2017 & 2021 & 2028)

1.4.2 Global Blinatumomab Sales in Volume (2017-2028)

1.4.3 Global Blinatumomab Price (2017-2028)

1.5 Global Blinatumomab Production Capacity Analysis

1.5.1 Global Blinatumomab Total Production Capacity (2017-2028)

1.5.2 Global Blinatumomab Production Capacity by Geographic Region

1.6 Market Drivers, Restraints and Trends

1.6.1 Blinatumomab Market Drivers

1.6.2 Blinatumomab Market Restraints

1.6.3 Blinatumomab Trends Analysis

2 Manufacturers Profiles

2.1 Amgen

2.1.1 Amgen Details

2.1.2 Amgen Major Business

2.1.3 Amgen Blinatumomab Product and Services

2.1.4 Amgen Blinatumomab Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 Blinatumomab Breakdown Data by Manufacturer

3.1 Global Blinatumomab Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)

3.2 Global Blinatumomab Revenue by Manufacturer (2019, 2020, 2021, and 2022)

3.3 Key Manufacturer Market Position in Blinatumomab

3.4 Market Concentration Rate

3.4.1 Top 3 Blinatumomab Manufacturer Market Share in 2021

3.4.2 Top 6 Blinatumomab Manufacturer Market Share in 2021

3.5 Global Blinatumomab Production Capacity by Company: 2021 VS 2022

3.6 Manufacturer by Geography: Head Office and Blinatumomab Production Site

3.7 New Entrant and Capacity Expansion Plans

3.8 Mergers & Acquisitions

4 Market Analysis by Region

4.1 Global Blinatumomab Market Size by Region

4.1.1 Global Blinatumomab Sales in Volume by Region (2017-2028)

4.1.2 Global Blinatumomab Revenue by Region (2017-2028)

4.2 North America Blinatumomab Revenue (2017-2028)

4.3 Europe Blinatumomab Revenue (2017-2028)

4.4 Asia-Pacific Blinatumomab Revenue (2017-2028)

4.5 South America Blinatumomab Revenue (2017-2028)

4.6 Middle East and Africa Blinatumomab Revenue (2017-2028)

5 Market Segment by Type

5.1 Global Blinatumomab Sales in Volume by Type (2017-2028)

5.2 Global Blinatumomab Revenue by Type (2017-2028)

5.3 Global Blinatumomab Price by Type (2017-2028)

6 Market Segment by Application

6.1 Global Blinatumomab Sales in Volume by Application (2017-2028)

6.2 Global Blinatumomab Revenue by Application (2017-2028)

6.3 Global Blinatumomab Price by Application (2017-2028)

7 North America by Country, by Type, and by Application

7.1 North America Blinatumomab Sales by Type (2017-2028)

7.2 North America Blinatumomab Sales by Application (2017-2028)

7.3 North America Blinatumomab Market Size by Country

7.3.1 North America Blinatumomab Sales in Volume by Country (2017-2028)

7.3.2 North America Blinatumomab Revenue by Country (2017-2028)

7.3.3 United States Market Size and Forecast (2017-2028)

7.3.4 Canada Market Size and Forecast (2017-2028)

7.3.5 Mexico Market Size and Forecast (2017-2028)

8 Europe by Country, by Type, and by Application

8.1 Europe Blinatumomab Sales by Type (2017-2028)

8.2 Europe Blinatumomab Sales by Application (2017-2028)

8.3 Europe Blinatumomab Market Size by Country

8.3.1 Europe Blinatumomab Sales in Volume by Country (2017-2028)

8.3.2 Europe Blinatumomab Revenue by Country (2017-2028)

8.3.3 Germany Market Size and Forecast (2017-2028)

8.3.4 France Market Size and Forecast (2017-2028)

8.3.5 United Kingdom Market Size and Forecast (2017-2028)

8.3.6 Russia Market Size and Forecast (2017-2028)

8.3.7 Italy Market Size and Forecast (2017-2028)

9 Asia-Pacific by Region, by Type, and by Application

9.1 Asia-Pacific Blinatumomab Sales by Type (2017-2028)

9.2 Asia-Pacific Blinatumomab Sales by Application (2017-2028)

9.3 Asia-Pacific Blinatumomab Market Size by Region

9.3.1 Asia-Pacific Blinatumomab Sales in Volume by Region (2017-2028)

9.3.2 Asia-Pacific Blinatumomab Revenue by Region (2017-2028)

9.3.3 China Market Size and Forecast (2017-2028)

9.3.4 Japan Market Size and Forecast (2017-2028)

9.3.5 Korea Market Size and Forecast (2017-2028)

9.3.6 India Market Size and Forecast (2017-2028)

9.3.7 Southeast Asia Market Size and Forecast (2017-2028)

9.3.8 Australia Market Size and Forecast (2017-2028)

10 South America by Region, by Type, and by Application

10.1 South America Blinatumomab Sales by Type (2017-2028)

10.2 South America Blinatumomab Sales by Application (2017-2028)

10.3 South America Blinatumomab Market Size by Country

10.3.1 South America Blinatumomab Sales in Volume by Country (2017-2028)

10.3.2 South America Blinatumomab Revenue by Country (2017-2028)

10.3.3 Brazil Market Size and Forecast (2017-2028)

10.3.4 Argentina Market Size and Forecast (2017-2028)

11 Middle East & Africa by Country, by Type, and by Application

11.1 Middle East & Africa Blinatumomab Sales by Type (2017-2028)

11.2 Middle East & Africa Blinatumomab Sales by Application (2017-2028)

11.3 Middle East & Africa Blinatumomab Market Size by Country

11.3.1 Middle East & Africa Blinatumomab Sales in Volume by Country (2017-2028)

11.3.2 Middle East & Africa Blinatumomab Revenue by Country (2017-2028)

11.3.3 Turkey Market Size and Forecast (2017-2028)

11.3.4 Egypt Market Size and Forecast (2017-2028)

11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)

11.3.6 South Africa Market Size and Forecast (2017-2028)

12 Raw Material and Industry Chain

12.1 Raw Material of Blinatumomab and Key Manufacturers

12.2 Manufacturing Costs Percentage of Blinatumomab

12.3 Blinatumomab Production Process

12.4 Blinatumomab Industrial Chain

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.2 Blinatumomab Typical Distributors

13.3 Blinatumomab Typical Customers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Research Process and Data Source

15.3 Disclaimer

List of Tables

Table 1. Global Blinatumomab Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 2. Global Blinatumomab Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 3. Amgen Basic Information, Manufacturing Base and Competitors

Table 4. Amgen Major Business

Table 5. Amgen Blinatumomab Product and Services

Table 6. Amgen Blinatumomab Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 7. Global Blinatumomab Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)

Table 8. Global Blinatumomab Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)

Table 9. Market Position of Manufacturers in Blinatumomab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021

Table 10. Global Blinatumomab Production Capacity by Company, (K Units): 2020 VS 2021

Table 11. Head Office and Blinatumomab Production Site of Key Manufacturer

Table 12. Blinatumomab New Entrant and Capacity Expansion Plans

Table 13. Blinatumomab Mergers & Acquisitions in the Past Five Years

Table 14. Global Blinatumomab Sales by Region (2017-2022) & (K Units)

Table 15. Global Blinatumomab Sales by Region (2023-2028) & (K Units)

Table 16. Global Blinatumomab Revenue by Region (2017-2022) & (USD Million)

Table 17. Global Blinatumomab Revenue by Region (2023-2028) & (USD Million)

Table 18. Global Blinatumomab Sales by Type (2017-2022) & (K Units)

Table 19. Global Blinatumomab Sales by Type (2023-2028) & (K Units)

Table 20. Global Blinatumomab Revenue by Type (2017-2022) & (USD Million)

Table 21. Global Blinatumomab Revenue by Type (2023-2028) & (USD Million)

Table 22. Global Blinatumomab Price by Type (2017-2022) & (USD/Unit)

Table 23. Global Blinatumomab Price by Type (2023-2028) & (USD/Unit)

Table 24. Global Blinatumomab Sales by Application (2017-2022) & (K Units)

Table 25. Global Blinatumomab Sales by Application (2023-2028) & (K Units)

Table 26. Global Blinatumomab Revenue by Application (2017-2022) & (USD Million)

Table 27. Global Blinatumomab Revenue by Application (2023-2028) & (USD Million)

Table 28. Global Blinatumomab Price by Application (2017-2022) & (USD/Unit)

Table 29. Global Blinatumomab Price by Application (2023-2028) & (USD/Unit)

Table 30. North America Blinatumomab Sales by Country (2017-2022) & (K Units)

Table 31. North America Blinatumomab Sales by Country (2023-2028) & (K Units)

Table 32. North America Blinatumomab Revenue by Country (2017-2022) & (USD Million)

Table 33. North America Blinatumomab Revenue by Country (2023-2028) & (USD Million)

Table 34. North America Blinatumomab Sales by Type (2017-2022) & (K Units)

Table 35. North America Blinatumomab Sales by Type (2023-2028) & (K Units)

Table 36. North America Blinatumomab Sales by Application (2017-2022) & (K Units)

Table 37. North America Blinatumomab Sales by Application (2023-2028) & (K Units)

Table 38. Europe Blinatumomab Sales by Country (2017-2022) & (K Units)

Table 39. Europe Blinatumomab Sales by Country (2023-2028) & (K Units)

Table 40. Europe Blinatumomab Revenue by Country (2017-2022) & (USD Million)

Table 41. Europe Blinatumomab Revenue by Country (2023-2028) & (USD Million)

Table 42. Europe Blinatumomab Sales by Type (2017-2022) & (K Units)

Table 43. Europe Blinatumomab Sales by Type (2023-2028) & (K Units)

Table 44. Europe Blinatumomab Sales by Application (2017-2022) & (K Units)

Table 45. Europe Blinatumomab Sales by Application (2023-2028) & (K Units)

Table 46. Asia-Pacific Blinatumomab Sales by Region (2017-2022) & (K Units)

Table 47. Asia-Pacific Blinatumomab Sales by Region (2023-2028) & (K Units)

Table 48. Asia-Pacific Blinatumomab Revenue by Region (2017-2022) & (USD Million)

Table 49. Asia-Pacific Blinatumomab Revenue by Region (2023-2028) & (USD Million)

Table 50. Asia-Pacific Blinatumomab Sales by Type (2017-2022) & (K Units)

Table 51. Asia-Pacific Blinatumomab Sales by Type (2023-2028) & (K Units)

Table 52. Asia-Pacific Blinatumomab Sales by Application (2017-2022) & (K Units)

Table 53. Asia-Pacific Blinatumomab Sales by Application (2023-2028) & (K Units)

Table 54. South America Blinatumomab Sales by Country (2017-2022) & (K Units)

Table 55. South America Blinatumomab Sales by Country (2023-2028) & (K Units)

Table 56. South America Blinatumomab Revenue by Country (2017-2022) & (USD Million)

Table 57. South America Blinatumomab Revenue by Country (2023-2028) & (USD Million)

Table 58. South America Blinatumomab Sales by Type (2017-2022) & (K Units)

Table 59. South America Blinatumomab Sales by Type (2023-2028) & (K Units)

Table 60. South America Blinatumomab Sales by Application (2017-2022) & (K Units)

Table 61. South America Blinatumomab Sales by Application (2023-2028) & (K Units)

Table 62. Middle East & Africa Blinatumomab Sales by Region (2017-2022) & (K Units)

Table 63. Middle East & Africa Blinatumomab Sales by Region (2023-2028) & (K Units)

Table 64. Middle East & Africa Blinatumomab Revenue by Region (2017-2022) & (USD Million)

Table 65. Middle East & Africa Blinatumomab Revenue by Region (2023-2028) & (USD Million)

Table 66. Middle East & Africa Blinatumomab Sales by Type (2017-2022) & (K Units)

Table 67. Middle East & Africa Blinatumomab Sales by Type (2023-2028) & (K Units)

Table 68. Middle East & Africa Blinatumomab Sales by Application (2017-2022) & (K Units)

Table 69. Middle East & Africa Blinatumomab Sales by Application (2023-2028) & (K Units)

Table 70. Blinatumomab Raw Material

Table 71. Key Manufacturers of Blinatumomab Raw Materials

Table 72. Direct Channel Pros & Cons

Table 73. Indirect Channel Pros & Cons

Table 74. Blinatumomab Typical Distributors

Table 75. Blinatumomab Typical Customers

List of Figures

Figure 1. Blinatumomab Picture

Figure 2. Global Blinatumomab Revenue Market Share by Type in 2021

Figure 3. Prefilled

Figure 4. Non-prefilled

Figure 5. Global Blinatumomab Revenue Market Share by Application in 2021

Figure 6. Hospital

Figure 7. Pharmacy

Figure 8. Global Blinatumomab Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028

Figure 9. Global Blinatumomab Revenue and Forecast (2017-2028) & (USD Million)

Figure 10. Global Blinatumomab Sales (2017-2028) & (K Units)

Figure 11. Global Blinatumomab Price (2017-2028) & (USD/Unit)

Figure 12. Global Blinatumomab Production Capacity (2017-2028) & (K Units)

Figure 13. Global Blinatumomab Production Capacity by Geographic Region: 2022 VS 2028

Figure 14. Blinatumomab Market Drivers

Figure 15. Blinatumomab Market Restraints

Figure 16. Blinatumomab Market Trends

Figure 17. Global Blinatumomab Sales Market Share by Manufacturer in 2021

Figure 18. Global Blinatumomab Revenue Market Share by Manufacturer in 2021

Figure 19. Blinatumomab Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021

Figure 20. Top 3 Blinatumomab Manufacturer (Revenue) Market Share in 2021

Figure 21. Top 6 Blinatumomab Manufacturer (Revenue) Market Share in 2021

Figure 22. Global Blinatumomab Sales Market Share by Region (2017-2028)

Figure 23. Global Blinatumomab Revenue Market Share by Region (2017-2028)

Figure 24. North America Blinatumomab Revenue (2017-2028) & (USD Million)

Figure 25. Europe Blinatumomab Revenue (2017-2028) & (USD Million)

Figure 26. Asia-Pacific Blinatumomab Revenue (2017-2028) & (USD Million)

Figure 27. South America Blinatumomab Revenue (2017-2028) & (USD Million)

Figure 28. Middle East & Africa Blinatumomab Revenue (2017-2028) & (USD Million)

Figure 29. Global Blinatumomab Sales Market Share by Type (2017-2028)

Figure 30. Global Blinatumomab Revenue Market Share by Type (2017-2028)

Figure 31. Global Blinatumomab Price by Type (2017-2028) & (USD/Unit)

Figure 32. Global Blinatumomab Sales Market Share by Application (2017-2028)

Figure 33. Global Blinatumomab Revenue Market Share by Application (2017-2028)

Figure 34. Global Blinatumomab Price by Application (2017-2028) & (USD/Unit)

Figure 35. North America Blinatumomab Sales Market Share by Type (2017-2028)

Figure 36. North America Blinatumomab Sales Market Share by Application (2017-2028)

Figure 37. North America Blinatumomab Sales Market Share by Country (2017-2028)

Figure 38. North America Blinatumomab Revenue Market Share by Country (2017-2028)

Figure 39. United States Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 40. Canada Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 41. Mexico Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 42. Europe Blinatumomab Sales Market Share by Type (2017-2028)

Figure 43. Europe Blinatumomab Sales Market Share by Application (2017-2028)

Figure 44. Europe Blinatumomab Sales Market Share by Country (2017-2028)

Figure 45. Europe Blinatumomab Revenue Market Share by Country (2017-2028)

Figure 46. Germany Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. France Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. United Kingdom Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Russia Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Italy Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Asia-Pacific Blinatumomab Sales Market Share by Region (2017-2028)

Figure 52. Asia-Pacific Blinatumomab Sales Market Share by Application (2017-2028)

Figure 53. Asia-Pacific Blinatumomab Sales Market Share by Region (2017-2028)

Figure 54. Asia-Pacific Blinatumomab Revenue Market Share by Region (2017-2028)

Figure 55. China Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Japan Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Korea Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. India Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Southeast Asia Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Australia Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. South America Blinatumomab Sales Market Share by Type (2017-2028)

Figure 62. South America Blinatumomab Sales Market Share by Application (2017-2028)

Figure 63. South America Blinatumomab Sales Market Share by Country (2017-2028)

Figure 64. South America Blinatumomab Revenue Market Share by Country (2017-2028)

Figure 65. Brazil Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Argentina Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Middle East & Africa Blinatumomab Sales Market Share by Type (2017-2028)

Figure 68. Middle East & Africa Blinatumomab Sales Market Share by Application (2017-2028)

Figure 69. Middle East & Africa Blinatumomab Sales Market Share by Region (2017-2028)

Figure 70. Middle East & Africa Blinatumomab Revenue Market Share by Region (2017-2028)

Figure 71. Turkey Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. Egypt Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. Saudi Arabia Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. South Africa Blinatumomab Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Manufacturing Cost Structure Analysis of Blinatumomab in 2021

Figure 76. Manufacturing Process Analysis of Blinatumomab

Figure 77. Blinatumomab Industrial Chain

Figure 78. Sales Channel: Direct Channel vs Indirect Channel

Figure 79. Methodology

Figure 80. Research Process and Data Source